1.Epidemiology Primary liver cancer is highly prevalent in Southeast Asia, Africa, and the Western Pacific region, and 564,000 new liver cancers are found worldwide every year, accounting for 4% of malignant tumors. It is rare in Europe, America, North America and the Middle East. The incidence rate in China is about 10 times higher than that in Europe and the United States, mainly in the southeast coastal areas, Tongan County, Fujian Province and Qidong, Jiangsu Province. The ratio of men to women in China is 3-4:1, and the age is mainly 40-55 years old. The relationship between liver cancer and cirrhosis is also a concern. 50%-90% of liver cancers are combined with cirrhosis, mostly large nodular cirrhosis. The risk factors for the progression of cirrhosis to liver cancer are: age, infection, duration, male, alcoholism and overlapping infection of HBV and HCV. Recognized formula HBV 0r HCV?cirrhosis? Hepatocellular carcinoma 3. Multimodal combination therapy Hepatectomy + TACE Hepatectomy + biologic therapy TACE + hepatectomy TACE + RFA/PEI RFA + PEI TACE + radiotherapy TACE + biologic therapy 4. Principles of action of interventional therapy (a) Perfusion chemotherapy (TAI) The effectiveness of anticancer drugs in killing cancer cells depends on the product of effective drug concentration and duration Reduction of target organ The blood flow of target organs and vascular retardation therapy can reduce the binding of drugs with plasma proteins. Super-selective cannulation can increase the blood drug concentration. The liver has a good compensatory function, and the hepatic artery can easily form collateral circulation after embolization. 6. Physical energy such as curing, electrocoagulation, condensation, radiofrequency heating, etc. are used to make tumor cells die. 7. Interventional treatment for small liver cancer Traditional surgical theory holds that surgery is preferred for small liver cancer, but the recurrence rate of small liver cancer is 43.5% 5 years after resection. The number of cases available is not enough to shake the principle that surgery is the first choice for small hepatocellular carcinoma.